Obstructive Sleep Apnea Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight

DelveInsight’s Obstructive Sleep Apnea Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NV, UNITED STATES, January 20, 2025 /EINPresswire.com/ -- The Obstructive Sleep Apnea market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obstructive Sleep Apnea pipeline products will significantly revolutionize the Obstructive Sleep Apnea market dynamics.

DelveInsight’s “Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obstructive Sleep Apnea, historical and forecasted epidemiology as well as the Obstructive Sleep Apnea market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Obstructive Sleep Apnea market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obstructive Sleep Apnea Market Forecast

Some of the key facts of the Obstructive Sleep Apnea Market Report:
• The Obstructive Sleep Apnea market size was valued approximately USD 359 million in 2023 and is anticipated to grow with a significant CAGR of 17% during the study period (2020-2034).
• In Jan 2025, Mineralys Therapeutics, Inc. announced that the FDA has approved its IND application for a Phase 2 clinical trial to assess lorundrostat for the treatment of obstructive sleep apnea (OSA) and hypertension. The trial is set to begin in the first quarter of 2025.
• In December 2024, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Zepbound^® (tirzepatide) as the first and only prescription treatment for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. Zepbound is intended to help alleviate sleep disorders in adults affected by both OSA and obesity.
• In June 2024, Eli Lilly and Company (NYSE: LLY) shared detailed findings from the SURMOUNT-OSA Phase III clinical trials, which assessed tirzepatide injection (10 mg or 15 mg) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, both with and without positive airway pressure (PAP) therapy. Lilly has submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the US Food and Drug Administration (FDA) and plans to begin submissions to other global regulatory authorities in the coming weeks.
• In April 2024, Incannex's IHL-42X, a cannabinoid-based combination product, is progressing into phase II/III trials for obstructive sleep apnea (OSA). Early results have shown promise, enhancing its market potential. The trials, which will begin in the US and expand to Europe, are designed to tackle patient non-compliance with PAP devices.
• In May 2024, Incannex Healthcare Inc., a pharmaceutical company focused on developing innovative medicinal cannabinoid and psychedelic therapies, announced that patient dosing has begun in its Phase II/III clinical trial to evaluate the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA).
• In 2023, the US held the largest market share for Obstructive Sleep Apnea treatments among the 7MM, valued at around USD 247 million. This market is projected to grow at a compound annual growth rate (CAGR) of 17.3% by 2034.
• In 2023, Germany had the largest Obstructive Sleep Apnea market size among EU countries, reaching approximately USD 23 million, while the UK had the smallest market size, with about USD 12 million.
• In 2023, the Obstructive Sleep Apnea Treatment market size in Japan was approximately USD 24 million.
• According to DelveInsight's assessment, the US had the highest number of diagnosed Obstructive Sleep Apnea prevalent cases in 2023 among the 7MM, representing 54% of the total with approximately 13,763 thousand cases.
• In 2023, the analysis of Obstructive Sleep Apnea (OSA) cases across the 7MM revealed that the highest prevalence was observed in individuals aged 65 and above, with approximately 8,870 thousand cases. Conversely, the lowest prevalence was found in the 19–24 years age group, with about 179 thousand cases. citeturn0search1
• Analysis shows that in Japan, the highest prevalence of Obstructive Sleep Apnea is found in the 65 and above age group, with approximately 1,732 thousand cases, while the lowest prevalence is in the 19─24 years group, with around 35 thousand cases.
• In 2023, the US recorded approximately 4,275 thousand mild Obstructive Sleep Apnea (OSA) cases, 3,280 thousand moderate cases, and 6,208 thousand severe cases. These figures are expected to steadily increase from 2024 to 2034, indicating a growing trend in the severity of OSA cases.
• Key Obstructive Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma, Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Desitin Arzneimittel GmbH, and others
• Key Obstructive Sleep Apnea Therapies: AD109, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), TS-142, TAK-925, BAY 2586116, Sulthiame, and others
• The Obstructive Sleep Apnea epidemiology based on gender analyzed that in 2022, 61% cases of OSA were of males, while 39% cases were of Females in the 7MM
• The Obstructive Sleep Apnea market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obstructive Sleep Apnea pipeline products will significantly revolutionize the Obstructive Sleep Apnea market dynamics.

Obstructive Sleep Apnea Overview
Obstructive sleep apnea (OSA) is a sleep disorder characterized by repeated episodes of complete or partial blockage of the upper airway during sleep, leading to pauses in breathing or shallow breathing. These episodes, known as apneas or hypopneas, can occur multiple times throughout the night and disrupt normal sleep patterns.

Get a Free sample for the Obstructive Sleep Apnea Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Obstructive Sleep Apnea Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Obstructive Sleep Apnea Epidemiology Segmentation:
The Obstructive Sleep Apnea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
• Total Prevalence of Obstructive Sleep Apnea
• Prevalent Cases of Obstructive Sleep Apnea by severity
• Gender-specific Prevalence of Obstructive Sleep Apnea
• Diagnosed Cases of Episodic and Chronic Obstructive Sleep Apnea

Download the report to understand which factors are driving Obstructive Sleep Apnea epidemiology trends @ Obstructive Sleep Apnea Epidemiology Forecast

Obstructive Sleep Apnea Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obstructive Sleep Apnea market or expected to get launched during the study period. The analysis covers Obstructive Sleep Apnea market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Obstructive Sleep Apnea Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obstructive Sleep Apnea Therapies and Key Companies
• AD109: Apnimed
• Tirzepatide: Eli Lilly and Company
• AD113: Apnimed
• SUNOSI (Solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals
• OZAWADE (Pitolisant): Bioprojet Pharma
• TS-142: Taisho Pharmaceutical Co., Ltd.
• TAK-925: Takeda
• BAY 2586116: Bayer
• Sulthiame: Desitin Arzneimittel GmbH
• Lemborexant : Eisai

Obstructive Sleep Apnea Market Drivers
• Increase in prevalence of Obstructive Sleep Apnea (OSA), rising awareness of the disorder are some of the important factors that are fueling the Obstructive Sleep Apnea Market.

Obstructive Sleep Apnea Market Barriers
• However, lack of Approved Drugs, complexity of OSA pathogenesis and other factors are creating obstacles in the Obstructive Sleep Apnea Market growth.

Scope of the Obstructive Sleep Apnea Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Obstructive Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma, Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Desitin Arzneimittel GmbH, and others
• Key Obstructive Sleep Apnea Therapies: AD109, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), TS-142, TAK-925, BAY 2586116, Sulthiame, and others
• Obstructive Sleep Apnea Therapeutic Assessment: Obstructive Sleep Apnea current marketed and Obstructive Sleep Apnea emerging therapies
• Obstructive Sleep Apnea Market Dynamics: Obstructive Sleep Apnea market drivers and Obstructive Sleep Apnea market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Obstructive Sleep Apnea Unmet Needs, KOL’s views, Analyst’s views, Obstructive Sleep Apnea Market Access and Reimbursement

To know more about Obstructive Sleep Apnea companies working in the treatment market, visit @ Obstructive Sleep Apnea Clinical Trials and Therapeutic Assessment

Table of Contents
1. Obstructive Sleep Apnea Market Report Introduction
2. Executive Summary for Obstructive Sleep Apnea
3. SWOT analysis of Obstructive Sleep Apnea
4. Obstructive Sleep Apnea Patient Share (%) Overview at a Glance
5. Obstructive Sleep Apnea Market Overview at a Glance
6. Obstructive Sleep Apnea Disease Background and Overview
7. Obstructive Sleep Apnea Epidemiology and Patient Population
8. Country-Specific Patient Population of Obstructive Sleep Apnea
9. Obstructive Sleep Apnea Current Treatment and Medical Practices
10. Obstructive Sleep Apnea Unmet Needs
11. Obstructive Sleep Apnea Emerging Therapies
12. Obstructive Sleep Apnea Market Outlook
13. Country-Wise Obstructive Sleep Apnea Market Analysis (2020–2034)
14. Obstructive Sleep Apnea Market Access and Reimbursement of Therapies
15. Obstructive Sleep Apnea Market Drivers
16. Obstructive Sleep Apnea Market Barriers
17. Obstructive Sleep Apnea Appendix
18. Obstructive Sleep Apnea Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here